- Home
- PEGA vs BLCO Comparison
PEGA vs BLCO Comparison
Compare PEGA & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- BLCO
- Stock Information
- Founded
- PEGA 1983
- BLCO 1853
- Country
- PEGA United States
- BLCO Canada
- Employees
- PEGA N/A
- BLCO N/A
- Industry
- PEGA EDP Services
- BLCO Ophthalmic Goods
- Sector
- PEGA Technology
- BLCO Health Care
- Exchange
- PEGA Nasdaq
- BLCO Nasdaq
- Market Cap
- PEGA 6.9B
- BLCO 7.0B
- IPO Year
- PEGA 1996
- BLCO 2022
- Fundamental
- Price
- PEGA $86.86
- BLCO $19.69
- Analyst Decision
- PEGA Buy
- BLCO Buy
- Analyst Count
- PEGA 10
- BLCO 11
- Target Price
- PEGA $85.90
- BLCO $21.30
- AVG Volume (30 Days)
- PEGA 640.4K
- BLCO 523.5K
- Earning Date
- PEGA 10-23-2024
- BLCO 10-30-2024
- Dividend Yield
- PEGA 0.14%
- BLCO N/A
- EPS Growth
- PEGA N/A
- BLCO N/A
- EPS
- PEGA 1.36
- BLCO N/A
- Revenue
- PEGA $1,480,583,000.00
- BLCO $4,684,000,000.00
- Revenue This Year
- PEGA $5.40
- BLCO $17.44
- Revenue Next Year
- PEGA $7.09
- BLCO $6.18
- P/E Ratio
- PEGA $63.71
- BLCO N/A
- Revenue Growth
- PEGA 9.28
- BLCO 18.01
- 52 Week Low
- PEGA $44.07
- BLCO $13.16
- 52 Week High
- PEGA $91.54
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- PEGA 67.59
- BLCO 48.24
- Support Level
- PEGA $85.13
- BLCO $19.45
- Resistance Level
- PEGA $91.54
- BLCO $20.71
- Average True Range (ATR)
- PEGA 1.96
- BLCO 0.55
- MACD
- PEGA 0.35
- BLCO -0.15
- Stochastic Oscillator
- PEGA 65.31
- BLCO 16.67
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management, or BPM, with customer relationship management, or CRM, applications. The company focuses on enterprise-size customers, specifically within the financial, insurance, and healthcare fields.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.